Design Therapeutics Inc (DSGN) - Total Assets
Based on the latest financial reports, Design Therapeutics Inc (DSGN) holds total assets worth $211.77 Million USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See net asset quality index of Design Therapeutics Inc to measure how much of total assets are equity-financed.
Design Therapeutics Inc - Total Assets Trend (2019–2024)
This chart illustrates how Design Therapeutics Inc's total assets have evolved over time, based on quarterly financial data. Check Design Therapeutics Inc (DSGN) tangible net worth to evaluate the tangible quality of the company's equity base.
Design Therapeutics Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Design Therapeutics Inc's total assets of $211.77 Million consist of 98.4% current assets and 1.6% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 9.0% |
| Accounts Receivable | $1.26 Million | 0.5% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2024)
This chart illustrates how Design Therapeutics Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Design Therapeutics Inc.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Design Therapeutics Inc's current assets represent 98.4% of total assets in 2024, a decrease from 100.0% in 2019.
- Cash Position: Cash and equivalents constituted 9.0% of total assets in 2024, down from 85.6% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 0.5% of total assets.
Design Therapeutics Inc Competitors by Total Assets
Key competitors of Design Therapeutics Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €8.68 Billion |
|
CSL Ltd
AU:CSL
|
Australia | AU$39.54 Billion |
|
Tango Therapeutics Inc
NASDAQ:TNGX
|
USA | $398.69 Million |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩703.48 Billion |
|
SOLENO THERAPEUT. DL-001
F:6XC
|
Germany | €563.83 Million |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX
|
USA | $452.70 Million |
|
Tourmaline Bio Inc.
NASDAQ:TRML
|
USA | $269.30 Million |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230
|
China | CN¥1.32 Billion |
Design Therapeutics Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 18.71 | 34.61 | 15.55 |
| Quick Ratio | 18.71 | 34.61 | 15.50 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $197.86 Million | $249.81 Million | $33.90 Million |
Design Therapeutics Inc - Advanced Valuation Insights
This section examines the relationship between Design Therapeutics Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.61 |
| Latest Market Cap to Assets Ratio | 1.71 |
| Asset Growth Rate (YoY) | -13.0% |
| Total Assets | $252.09 Million |
| Market Capitalization | $430.65 Million USD |
Valuation Analysis
Above Book Valuation: The market values Design Therapeutics Inc's assets above their book value (1.71x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Design Therapeutics Inc's assets decreased by 13.0% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Design Therapeutics Inc (2019–2024)
The table below shows the annual total assets of Design Therapeutics Inc from 2019 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $252.09 Million | -12.96% |
| 2023-12-31 | $289.64 Million | -15.09% |
| 2022-12-31 | $341.14 Million | -12.65% |
| 2021-12-31 | $390.56 Million | +969.55% |
| 2020-12-31 | $36.52 Million | +40473.33% |
| 2019-12-31 | $90.00K | -- |
About Design Therapeutics Inc
Design Therapeutics, Inc. a clinical-stage biopharmaceutical company, research, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potenti… Read more